Sugi Predict

Sugi Predict / Compounds / SCHEMBL4299159

SCHEMBL4299159

SCHEMBL4299159

CC(C=O)N(C)C(=O)OC(C)(C)C

nearest known ligand 0.34

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 6/20 0.34
▸ HDAC6 Q9UBN7 2/20 0.33
▸ AAK1 Q2M2I8 2/20 0.33
▸ MMP13 P45452 1/20 0.33
▸ HDAC1 Q13547 1/20 0.32
▸ HDAC2 Q92769 1/20 0.32
▸ CA12 O43570 1/20 0.31
▸ CA14 Q9ULX7 1/20 0.31
▸ CA1 P00915 1/20 0.30
▸ CA2 P00918 1/20 0.30
▸ CA7 P43166 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8274243 1.00 CTSK (0.34) CTSKHDAC6AAK1MMP13HDAC1
SCHEMBL5559416 1.00 CTSK (0.34) CTSKHDAC6AAK1MMP13HDAC1
SCHEMBL24490826 0.82 NPSR1 (0.33) HDAC6AAK1MMP13HDAC1HDAC2
SCHEMBL23977802 0.82 NPSR1 (0.33) HDAC6AAK1MMP13HDAC1HDAC2
SCHEMBL30073859 0.82 NPSR1 (0.33) HDAC6AAK1MMP13HDAC1HDAC2
SCHEMBL52414 0.81 CTSK (0.33) CTSKHDAC6AAK1HDAC1HDAC2
SCHEMBL52415 0.81 CTSK (0.33) CTSKHDAC6AAK1HDAC1HDAC2
SCHEMBL5345861 0.79 AAK1 (0.35) HDAC6AAK1MMP13HDAC1HDAC2
SCHEMBL7468074 0.78 CTSK (0.33) CTSKHDAC6HDAC1HDAC2
SCHEMBL25170407 0.78 GABRP (0.38) HDAC6AAK1MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612414-B2 Nitrile SUMO inhibitors and uses thereof CIT THERAPEUTICS, INC. (US) 2026-04-28 — — US disclosed
EP-3912979-B1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2026-03-25 — — EP disclosed
US-20250197402-A1 Tyrosine Kinase Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2025-06-19 — — US disclosed
US-20240360148-A1 NITRILE SUMO INHIBITORS AND USES THEREOF CIT THERAPEUTICS LLC 2024-10-31 — — US disclosed
EP-4373825-A1 NITRILE SUMO INHIBITORS AND USES THEREOF Suvalent Therapeutics, Inc. (US) 2024-05-29 — — EP disclosed
CN-118103370-A Fused tetracyclic quinazoline derivatives as ERBB2 inhibitors 英莱汶公司 2024-05-28 — — CN disclosed
US-20230151012-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2023-05-18 — — US disclosed
WO-2023004376-A1 NITRILE SUMO INHIBITORS AND USES THEREOF Suvalent Therapeutics, Inc. (US) 2023-01-26 — — WO disclosed
EP-4112618-A1 TYROSINE KINASE INHIBITORS Principia Biopharma Inc. (US) 2023-01-04 — — EP disclosed
WO-2022140769-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN THERAPEUTICS, INC. (US) 2022-06-30 — — WO disclosed
WO-2014036016-A1 BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2014-03-06 — — WO disclosed
WO-2013127729-A1 6 - ALKYNYL PYRIDINES AS SMAC MIMETICS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-09-06 — — WO disclosed
US-20120245137-A1 ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2012-09-27 — — US disclosed
US-8188083-B2 Triazolopyridazines ABBOTT LABORATORIES (US) 2012-05-29 — — US disclosed
US-20090270402-A1 Novel triazolopyridazines ABBVIE INC. 2009-10-29 — — US disclosed
US-7312343-B2 N-benzyl-protected dialkyl acetal derivatives undergo desired aldol reaction with high diastereoselectivity using a Mukaiyama aldol reaction; intermediates in the synthesis of other products, including, e.g. Dolastatin 10 HOFFMANN-LA ROCHE INC. (US) 2007-12-25 — — US disclosed
EP-1756038-A1 SYNTHESIS OF AMINO-ALKOXY-HEPTANOIC ALKYL ESTER F.HOFFMANN-LA ROCHE AG (CH) 2007-02-28 — — EP disclosed
WO-2005118525-A1 SYNTHESIS OF AMINO-ALKOXY-HEPTANOIC ALKYL ESTER F.HOFFMANN-LA ROCHE AG (CH) 2005-12-15 — — WO disclosed
US-20050272665-A1 Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters F. HOFFMANN-LA ROCHE AG (CH) 2005-12-08 — — US disclosed
US-5726185-A BINDING OF ADHESIVE PROTEINS TO BLOOD PLATELET AGGREGATION AND CELL TO CELL ADHESION HOFFMANN-LA ROCHE INC. (US) 1998-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270402-A1 Novel triazolopyridazines MAP3K5, MAP3K1, MAP3K2 CTSK 1838/4885HDAC6 1170/4885AAK1 342/4885
US-20240360148-A1 NITRILE SUMO INHIBITORS AND USES THEREOF SUMO1, SUMO3, SUMO2 CTSK 2620/4885HDAC6 2286/4885AAK1 2995/4885
US-20120245137-A1 ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CACNA1I, CACNA1G, CACNA1A CTSK 796/4885HDAC6 1312/4885AAK1 1875/4885
US-12612414-B2 Nitrile SUMO inhibitors and uses thereof SUMO1, SUMO3, PSMB6 CTSK 2087/4885HDAC6 1262/4885AAK1 3089/4885
US-20230151012-A1 TYROSINE KINASE INHIBITORS BTK, LYN, SYK CTSK 1010/4885HDAC6 799/4885AAK1 698/4885
US-20050272665-A1 Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters ALDH7A1, BCAT1, BCAT2 CTSK 2415/4885HDAC6 4041/4885AAK1 2093/4885
US-20250197402-A1 Tyrosine Kinase Inhibitors BTK, LYN, SYK CTSK 1010/4885HDAC6 799/4885AAK1 698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.